Tiger Brokers

China Traditional Chinese Medicine FY2025 revenue fell 10.7% to RMB 14.74 billion, adjusted net profit dropped 47.5% to RMB 333.35 million

Reuters
Mar 20
<a href="https://laohu8.com/S/CHIZF">China Traditional Chinese Medicine</a> FY2025 revenue fell 10.7% to RMB 14.74 billion, adjusted net profit dropped 47.5% to RMB 333.35 million
  • China Traditional Chinese Medicine published an annual results announcement for the year ended Dec. 31, 2025.
  • Revenue fell 10.7% to RMB14.74 billion, while gross profit declined 9.7% to RMB7.09 billion.
  • The company reported a net loss of RMB458.09 million and a basic loss per share of 6.79 RMB cents.
  • By segment, revenue from Chinese medicinal herbs integration dropped 40.2% to RMB829.72 million due to exiting high-risk, low-margin business and lower herb selling prices, and concentrated TCM granules revenue fell 12.5% to RMB6.1 billion amid volume-based procurement and tougher competition.
  • Chairman Yang Jun said 2026 priorities include improving efficiency and cost structure, strengthening whole-chain control from medicinal materials to preparations, and increasing investment in evidence-based studies and innovative TCM R&D.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260320-12061642), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10